COMPANY PROFILE

Inipharm

Explore full profile

Developing treatments for severe liver disease with highly validated approaches to address unmet medical needs

Bellevue, United StatesFounded 2018

Valuation $100–250M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Inipharm

Inipharm is a biopharmaceutical company focused on developing innovative treatments for severe liver diseases. The company targets conditions with significant unmet medical needs, leveraging highly validated scientific approaches to create effective therapies. Inipharm primarily serves patients suffering from liver diseases, healthcare providers, and the broader medical community. Operating within the biopharmaceutical market, the company employs a research and development-driven business model, investing heavily in scientific research to discover and develop new drugs. Revenue is generated through the successful commercialization of these therapies, partnerships with larger pharmaceutical companies, and potential acquisitions. The company's leadership team boasts extensive experience in the pharmaceutical industry, with a track record of successful product development and company growth.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Bellevue, United States
Employees: 5
Open positions: None listed
Dealroom signal: 21.6/100
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Nov 2020	$35M	$140M	Frazier Healthcare Partners · Jubilant Biosys · 5AM Ventures · Wu Capital	—

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Inipharm website traffic

Latest recorded traffic for Inipharm is 1.8K monthly website visits, up 28.6% over the last three months. Inipharm's team declined 54.5% over the past year.

Latest monthly visits1.8K 3-month web change+28.6% 1-year team growth-54.5%

Monthly website visitsMay 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

5V5AM Ventures
WCWu Capital
FPFrazier Healthcare Partners
JBJubilant Biosys

Other known investors1 additional known investor

FSFrazier Life Sciences

Talent

Book a demo to see the people

Team profiled 1 named & role-tagged

Founders /100 quality score

Key operators quality score

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Inipharm on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inipharm’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.